Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (The Framingham Heart Study)

Colleen Sam, Joseph M. Massaro, Ralph B. D'Agostino, Daniel Levy, Jarvis W. Lambert, Philip A. Wolf, Emelia J. Benjamin

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF. Anticoagulant use increased significantly in the 393 men and women (mean ages 72.5 and 79.0 years, respectively) who developed AF over the observation period: aspirin use increased from 14% to 39% in men and from 19% to 33% in women, and warfarin use increased from 10% to 39% in men and from 17% to 38% in women. There were no significant gender differences in anticoagulant use (p = 0.61), but participants using warfarin were younger. A total of 65 participants (17%) had major bleeding complications ≤5 years after initial AF. Age was not a significant predictor of bleeding.

Original languageEnglish (US)
Pages (from-to)947-951
Number of pages5
JournalAmerican Journal of Cardiology
Volume94
Issue number7
DOIs
StatePublished - Oct 1 2004

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (The Framingham Heart Study)'. Together they form a unique fingerprint.

  • Cite this